Tracy Curley is recorded as Board Member at iSpecimen Inc. (ISPC) since May 24, 2023 and CEO at iSpecimen Inc. (ISPC). The newest filing on record that lists Tracy Curley as CEO at iSpecimen Inc. (ISPC) is dated April 10, 2023. iSpecimen Inc. reported in an 8-K filed November 12, 2024 that Tracy Curley resigned as member of the Board of Directors, effective November 8, 2024. iSpecimen Inc. reported in an 8-K filed May 25, 2023 that Tracy Curley was appointed Class II director, effective May 24, 2023. iSpecimen Inc. reported in an 8-K filed January 10, 2023 that Tracy Curley was appointed Chief Executive Officer, effective January 9, 2023. Equibles holds 4 filed executive changes naming Tracy Curley; each is listed under recent activity with its source filing. The proxy statement of iSpecimen Inc. reports total compensation of $329,314 for Tracy Curley in fiscal 2024, including a base salary of $329,314. Disclosed compensation is on record for 5 fiscal years. Tracy Curley has spoken on 10 earnings calls across 1 company, most recently for iSpecimen Inc. on March 14, 2024. iSpecimen Inc. is classified in the Diagnostics & Research industry within the Healthcare sector. Other leadership on record at iSpecimen Inc. includes Katharyn Field (CEO), Robert Bradley Lim (CEO and Board Member), Shahin Behroyan (CEO) and 7 others.
“In addition, on November 8, 2024, Ms. Curley resigned as a member of the Board of Directors (the "Board"), due to differences between Ms. Curley and the Board regarding the future direction of the Company.”
iSpecimen Inc. Form 8-K, filed November 12, 2024
· Read the filing
iSpecimen Inc. Form 8-K, filed May 25, 2023
· Read the filing
Tracy Curley on recent calls
“Throughout 2023, we worked diligently to streamline our operations, reduce costs and right-size our business. By driving operational efficiencies throughout the company, we are increasingly able to realize the true value of the iSpecimen Marketplace quarter-over-quarter and even month-to-month.”
“I'd like to take this opportunity to discuss how our recent initiatives to rightsize our business and enhance our operational structure and processes are paving the way for a new stage of future growth for iSpecimen.”
“Today, I will begin with an overview of the second quarter, including a brief update on the impact of the current economic environment on our business and the progress of our operational initiatives.”
“Good morning, everyone, and welcome to iSpecimen First Quarter 2023 Results Conference Call. With us on today's call is Benjamin Beilak, Chief Information Officer; and Eric Langlois, Chief Revenue Officer.”
“I will begin with a review of current business and operational activities and then our financial performance for the 12 months ended December 31, 2022. We will then open the call for questions.”
